Onconetix, Inc. (ONCO) Latest Company News

Oct 26, 2026, 21:03 UTC
Onconetix announced that its board approved a one-for-ten reverse stock split of its outstanding common stock, expected to take effect on November 6, 2026.
Source:
- globenewswire.com
Oct 23, 2026, 11:30 UTC
Realbotix LLC agreed to an additional US$500,000 advance under its bridge loan from Onconetix.
Source:
- businesswire.com
- globenewswire.com
Sep 24, 2026, 16:30 UTC
SRX Global added a minority investment in Onconetix (Nasdaq: ONCO) ahead of the anticipated closing of the Realbotix LLC acquisition.
Source:
- globenewswire.com
Sep 14, 2026, 15:03 UTC
Onconetix, Inc. agreed to lend Realbotix, LLC up to $5.0 million under an unsecured grid promissory note, with $2.5 million advanced initially, maturing September 11, 2027.
Sep 14, 2026, 11:30 UTC
Realbotix LLC, a wholly owned subsidiary of Realbotix Corp., entered into an unsecured bridge loan facility with Onconetix, Inc. in connection with their proposed merger.
Source:
Sep 3, 2026, 12:30 UTC
Onconetix entered into a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.
Source:
- globenewswire.com
Aug 6, 2026, 12:30 UTC
Realbotix, the acquisition target of Onconetix, secured an agreement with a streaming platform to feature its humanoid robot in an upcoming episode of an Emmy-winning series.
Source:
- globenewswire.com
Jul 29, 2026, 00:00 UTC
Onconetix, Inc. entered into a committed equity facility agreement allowing it to sell up to $750 million of its common stock over time at prevailing market prices.
Jul 29, 2026, 00:00 UTC
Onconetix, Inc. signed a securities purchase agreement for a $30,249,600 Series F PIPE financing, issuing 37,812 shares of Series F convertible preferred stock at $1,000 per share.

ONCO

Onconetix announced that its board approved a one-for-ten reverse stock split of its outstanding common stock, expected to take effect on November 6, 2026.

Realbotix LLC agreed to an additional US$500,000 advance under its bridge loan from Onconetix.

SRX Global added a minority investment in Onconetix (Nasdaq: ONCO) ahead of the anticipated closing of the Realbotix LLC acquisition.

Onconetix, Inc. agreed to lend Realbotix, LLC up to $5.0 million under an unsecured grid promissory note, with $2.5 million advanced initially, maturing September 11, 2027.

Realbotix LLC, a wholly owned subsidiary of Realbotix Corp., entered into an unsecured bridge loan facility with Onconetix, Inc. in connection with their proposed merger.

Onconetix entered into a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.

Realbotix, the acquisition target of Onconetix, secured an agreement with a streaming platform to feature its humanoid robot in an upcoming episode of an Emmy-winning series.

Onconetix, Inc. entered into a committed equity facility agreement allowing it to sell up to $750 million of its common stock over time at prevailing market prices.

Onconetix, Inc. signed a securities purchase agreement for a $30,249,600 Series F PIPE financing, issuing 37,812 shares of Series F convertible preferred stock at $1,000 per share.